WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted
anticancer therapies using its antibody-drug conjugate (ADC) technology,
today announced the appointment of Richard J. Gregory, Ph.D., as
Executive Vice President, Research and Chief Scientific Officer (CSO),
reporting to ImmunoGen President and CEO, Daniel Junius. Dr. Gregory
will join the Company on January 5, 2015, at which time current CSO,
John Lambert, Ph.D., will assume the position of Executive Vice
President, Distinguished Research Fellow. Dr. Gregory brings to
ImmunoGen deep scientific and research management experience, most
recently serving as senior vice president and head of research for the
Sanofi Genzyme Research & Development Center.
"Rich is a highly regarded leader who has extensive experience managing
effective biotechnology research," commented Mr. Junius. "I am excited
that he will be leading our research programs in support of bringing to
patients effective new anticancer therapies and continued expansion of
our technology portfolio and expertise."
Dr. Gregory has over twenty-five years of scientific and research
management experience, most of it gained in positions of increasing
responsibility at Genzyme. In 2003, he was appointed the head of
research at Genzyme, with responsibility for early research - from
discovery to development - for all Genzyme therapeutic areas, including
an ADC initiative. Following Sanofi's acquisition of Genzyme in 2011,
Dr. Gregory was appointed head of the Sanofi-Genzyme R&D Center and in
that capacity was responsible for Genzyme R&D from discovery through
regulatory approval.
During his tenure at Genzyme, a Sanofi Company, Dr. Gregory's teams made
critical contributions to the successful development and recent approval
of several products, including a groundbreaking oral therapy for
Gaucher's disease and a new treatment option for patients with active
multiple sclerosis. He received his doctorate in biochemistry from the
University of Massachusetts at Amherst, followed by post-doctoral
research in cancer genetics at the Worcester Foundation for Experimental
Biology. Dr. Gregory is the co-author of over 60 peer-reviewed
publications and has 23 issued U.S. patents.
Dr. Gregory succeeds Dr. Lambert, who joined ImmunoGen in 1987 and has
been the Company's CSO since 2008. Dr. Lambert assumes the newly created
role of Executive Vice President, Distinguished Research Fellow and
remains a member of ImmunoGen's executive team, reporting to Mr. Junius.
Mr. Junius noted, "John has played a key role in bringing ImmunoGen to
where it is today, with a validated technology that is making a
difference for patients with cancer. We are grateful that he will remain
very much involved with the Company - contributing his scientific
expertise - as part of the succession plan for our research
organization."
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®.
ImmunoGen has three wholly owned product candidates in clinical testing
with additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media